The goal of the Entrepreneurship in Biotechnology program is to bridge the separation of science and business education, to increase the effectiveness of scientists and engineers in management and finance settings and to help them envision leadership roles in science-based businesses. The program is directed by David Sable MD.
In addition to his academic work, Dr. Sable directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. He is a corporate director of Genenews, a Toronto-based diagnostics company and of Hamilton Thorne, a Massachusetts-based life science company. Dr. Sable graduated from the Wharton School and the University of Pennsylvania School of Medicine. His medical career included residency in obstetrics and gynecology at New York Hospital - Cornell Medical Center, fellowship at Brigham and Women's Hospital, and clinical practice at Harvard Medical School and MIT, before co-founding the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey.
After leaving clinical medicine at age 43, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations group. Dr. Sable has lectured on healthcare investing, healthcare policy, bioethics and biotechnology business development at the University of Pennsylvania, NYU, Columbia and Rutgers, and has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Genetic Engineering and Biotechnology News, and Nature Biotechnology.
D. Sable ((2010)) Portfolio managing for scientists Nature Biotechnology 28, 1131.